09:24 AM EST - Oncolytics Biotech Inc : Announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain. Highlights include; 7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by = 25%; also
T-cell expansion data correlate with tumor response, providing important proof-of-concept. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $2.14.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=4708597332831916
